Pharming Group NV (PHAR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pharming Group NV (PHAR) has a cash flow conversion efficiency ratio of 0.133x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($30.01 Million) by net assets ($225.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pharming Group NV - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Pharming Group NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Pharming Group NV carry for a breakdown of total debt and financial obligations.
Pharming Group NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharming Group NV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cadre Holdings Inc
NYSE:CDRE
|
0.067x |
|
thyssenkrupp nucera AG & Co. KGaA
XETRA:NCH2
|
0.001x |
|
Perpetual Limited
F:PVQ
|
0.041x |
|
Tianjin Benefo Tejing Electric Co Ltd
SHG:600468
|
0.001x |
|
Darma Henwa Tbk
JK:DEWA
|
0.091x |
|
Aavas Financiers Limited
NSE:AAVAS
|
-0.027x |
|
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
|
0.050x |
|
Mitra Adiperkasa Tbk
JK:MAPI
|
0.124x |
Annual Cash Flow Conversion Efficiency for Pharming Group NV (2005–2024)
The table below shows the annual cash flow conversion efficiency of Pharming Group NV from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see PHAR market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $221.06 Million | $-1.79 Million | -0.008x | +89.73% |
| 2023-12-31 | $218.78 Million | $-17.30 Million | -0.079x | -172.06% |
| 2022-12-31 | $204.64 Million | $22.46 Million | 0.110x | -44.05% |
| 2021-12-31 | $192.92 Million | $37.84 Million | 0.196x | -64.78% |
| 2020-12-31 | $150.16 Million | $83.63 Million | 0.557x | -11.83% |
| 2019-12-31 | $117.39 Million | $74.15 Million | 0.632x | -3.39% |
| 2018-12-31 | $70.64 Million | $46.19 Million | 0.654x | -67.83% |
| 2017-12-31 | $22.56 Million | $45.84 Million | 2.032x | +658.01% |
| 2016-12-31 | $28.89 Million | $-10.52 Million | -0.364x | +47.13% |
| 2015-12-31 | $26.06 Million | $-17.95 Million | -0.689x | -289.43% |
| 2014-12-31 | $36.29 Million | $-6.42 Million | -0.177x | +89.31% |
| 2013-12-31 | $6.92 Million | $-11.45 Million | -1.655x | -223.33% |
| 2012-12-31 | $-10.12 Million | $-13.58 Million | 1.342x | -89.84% |
| 2011-12-31 | $-1.54 Million | $-20.34 Million | 13.210x | +2676.91% |
| 2010-12-31 | $13.43 Million | $-6.89 Million | -0.513x | +64.11% |
| 2009-12-31 | $19.07 Million | $-27.24 Million | -1.428x | -75.31% |
| 2008-12-31 | $17.45 Million | $-14.21 Million | -0.815x | -30.04% |
| 2007-12-31 | $50.58 Million | $-31.69 Million | -0.626x | -59.15% |
| 2006-12-31 | $65.78 Million | $-25.89 Million | -0.394x | +12.20% |
| 2005-12-31 | $34.04 Million | $-15.26 Million | -0.448x | -- |
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more